Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy

Clinical Lung Cancer

Volumn 14, Issue 3, 2013, Pages 261-266

  Hayashi, Hidetoshi ^a   Okamoto, Isamu ^a   Taguri, Masataka ^b   Morita, Satoshi ^b   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Overall survival; Phase III trial; Progression free survival; Subsequent chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; INFORMATION RETRIEVAL; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY;

EID: 84879971900     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.09.006     Document Type: Article

References (23)

1. O.S. Breathnach, B. Freidlin, B. Conley Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results J Clin Oncol 19 2001 1734 1742
2. D.N. Carney Lung cancer - time to move on from chemotherapy N Engl J Med 346 2002 126 128
3. K. Hotta, K. Matsuo Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer J Thorac Oncol 2 2007 96
4. K. Hotta, K. Matsuo, H. Ueoka Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer J Clin Oncol 22 2004 3852 3859
5. C.G. Azzoli, S. Baker Jr, S. Temin American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 2009 6251 6266
6. H.A. Wakelee, P. Bernardo, D.H. Johnson Changes in the natural history of nonsmall cell lung cancer (NSCLC) - comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990 Cancer 106 2006 2208 2217
7. J.C. Soria, C. Massard, T. Le Chevalier Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 21 2010 2324 2332
8. H. Hayashi, I. Okamoto, S. Morita Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer Ann Oncol 23 2012 1537 1541
9. F.V. Fossella, R. DeVore, R.N. Kerr Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens The TAX 320 Non-Small Cell Lung Cancer Study Group J Clin Oncol 18 2000 2354 2362
10. N. Hanna, F.A. Shepherd, F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
11. E.S. Kim, V. Hirsh, T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
12. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
13. E.D. Saad, A. Katz, M. Buyse Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials J Clin Oncol 28 2010 1958 1962
14. R. DerSimonian, N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
15. K.R. Johnson, C. Ringland, B.J. Stokes Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis Lancet Oncol 7 2006 741 746
16. J.P. Sculier, K. Chansky, J.J. Crowley The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition J Thorac Oncol 3 2008 457 466
17. M.D. Brundage, D. Davies, W.J. Mackillop Prognostic factors in non-small cell lung cancer: a decade of progress Chest 122 2002 1037 1057
18. K.R. Broglio, D.A. Berry Detecting an overall survival benefit that is derived from progression-free survival J Natl Cancer Inst 101 2009 1642 1649
19. R. Ramlau, R. Gervais, M. Krzakowski Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer J Clin Oncol 24 2006 2800 2807
20. R.S. Herbst, Y. Sun, W.E. Eberhardt Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Lancet Oncol 11 2010 619 626
21. D.H. Lee, K. Park, J.H. Kim Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy Clin Cancer Res 16 2010 1307 1314
22. A.G. Pallis, S. Agelaki, A. Agelidou A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer BMC Cancer 10 2010 633
23. K. Takeda, S. Negoro, T. Tamura Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104) Ann Oncol 20 2009 835 841